RxDoctor Payments Data

Jesse Gabriel, MD

Family Medicine · Pittsburgh, PANPI 1760782601

Payments from drug & device makers

$777in general payments, 2019–2025

Across 43 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$329
  • Lilly USA, LLC$86
  • Merck$76
  • Exact Sciences$67
  • Pfizer$52
  • Boehringer Ingelheim$35
  • plus $133 from 5 others

What the payments were for

  • Food & beverage$777100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk18$329
Lilly USA, LLC5$86
Merck3$76
Exact Sciences4$67
Pfizer3$52
Boehringer Ingelheim2$35
Abbott2$35
Medicomp Inc2$32
GSK2$31
Watermark Medical, Inc.1$19
Viiv Healthcare Company1$16

How this compares

$777 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$114,059
Medicare patients
267
Services billed
1,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$84,593
XareltoRivaroxaban51$29,185
JardianceEmpagliflozin36$24,161
OzempicSemaglutide17$16,858
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,808
EntrestoSacubitril/Valsartan18$15,193
Aripiprazole38$11,343
MyrbetriqMirabegron17$10,818
Memantine Hcl78$7,439
Atorvastatin Calcium352$5,929
CreonLipase/Protease/Amylase12$5,696
Rivastigmine16$4,995
Donepezil Hcl133$4,226
Losartan Potassium179$3,627
Potassium Chloride139$3,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$84,593124 claims
Boehringer IngelheimJardiance$35$24,16136 claims
Novo NordiskOzempic$329$16,85817 claims
GSKTrelegy Ellipta$31$15,80817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →